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Abstract. Large protracted outbreaks of hepatitis E virus (HEV) have been documented in displaced populations
in Africa over the past decade though data are limited outside these exceptional settings. Serological studies can provide
insights useful for improving surveillance and disease control. We conducted an age-stratified serological survey using
samples previously collected for another research study from 206 residents of an internally displaced person camp in Juba,
South Sudan.We tested serum for anti-HEV antibodies (IgMand IgG) and estimated the prevalence of recent and historical
exposure to the virus. Using data on individuals’ serostatus, camp arrival date, and state of origin, we used catalytic
transmissionmodels to estimate the relative risk of HEV infection in the camp compared with that in the participants’ home
states. The age-adjusted seroprevalence of anti-HEV IgG was 71% (95% confidence interval = 63–78), and 4% had
evidence of recent exposure (IgM). We estimated HEV exposure rates to be more than 2-fold (hazard ratio = 2.3, 95%
credible interval = 0.3–5.8) higher in the camp than in the participants’ home states, although this difference was not
statistically significant. HEV transmission may be higher than previously appreciated, even in the absence of reported
cases. Improved surveillance in similar settings is needed to understand the burden of disease and minimize epidemic
impact through early detection and response.
INTRODUCTION
Hepatitis E virus (HEV) is thought to be responsible for
over 3 million symptomatic cases of acute hepatitis and
more than 50,000 deaths each year worldwide.1,2 Though
data from most of the world is scarce, a growing body
of evidence suggests that this acute viral infection may be
responsible for up to 10% of maternal deaths in some
areas like Bangladesh.3,4 Over the past decade, large out-
breaks of HEV have been reported in displaced populations
in east Africa, including a large outbreak in northern Uganda
responsible for more than 10,000 cases of acute jaundice
and a 2% case fatality ratio (CFR), and one in South Sudan
with more than 5,000 cases and a CFR in excess of 10%
among pregnant women.5,6
While access to safe water and improved sanitation will
halt most, if not all, HEV (genotypes 1 and 2) transmission,
water and sanitation interventions, including chlorine disin-
fection, in low-resource settings have proven less effective
than anticipated in reducing the risk of HEV infection.7 It
is possible that poor/inappropriate compliance with these
interventions is the reason they have not been effective,
but this disease is difficult to combat with conventional
approaches. Fortunately, a recombinant vaccine, HEV239
(Hecolin®; Innovax, Xiamen, China), has been shown to be
highly efficacious in reducing the incidence of clinical HEV
in a large randomized clinical trial in China.8 This vaccine is
not currently World Health Organization (WHO) prequalified;
however, the WHO recommends that it be considered for
use in outbreak settings.9 The vaccine has a three-dose
schedule, with the third dose given 6 months after the first,
making it less than ideal for outbreak response, although
data from the clinical trial suggest that reduced (one or two)
dose schedules may be highly protective.8
Insensitive surveillance systems, combined with a high
proportion of infected persons being asymptomatic and mildly
symptomatic, contribute to our poor understanding of HEV
epidemiology in resource-poor settings. This is especially true
in Africa, where the bulk of evidence comes from a handful of
large outbreaks over the past 10 years in Uganda, Sudan,
South Sudan, and surrounding countries.5–7,10,11 New insights
into the epidemiology of this disease, especially in settings
where the vaccine may be used in an outbreak, may help
provide important clues regarding how and where the vaccine
may have the greatest impact.
In South Sudan, confirmed HEV has been reported from
throughout the country over the past 10 years with most cases
reported from camps of displaced people, including an
epidemic that started in 2015.6,12,13 Outbreaks may be more
frequently reported from camps because HEV transmission
is higher in camps than in communities due to overcrowding
and often poor water and sanitation conditions. Alterna-
tively, the increased reporting from camps may simply
reflect the strength of surveillance systems in camps com-
pared with communities in the country and differential
awareness of this underappreciated disease.
Herein, we report results from a serological survey, using
samples originally collected for a cholera immunogenicity
study,14 among internally displaced persons (IDPs) in Juba,
South Sudan, to characterize patterns of historical exposure to
HEV and to better understand the relative risk of exposure
within the camp compared with the communities from where
participantswere displaced.
METHODS
Study setting. This study took place in the United Nations
House protection of civilians camp in Juba, South Sudan,
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which at the time housed more than 30,000 IDPs. When
ethnically motivated violence erupted in December 2013,
protection of civilian camps and other informal IDP camps
emerged and hosted people fleeing the threat of violence from
both near and far. Though the conditions within the camp had
improved since the start of the conflict, they remained only at
the threshold of acceptability in humanitarian emergencies
nearly 2 years later, with only approximately 15 L of safe
drinking water per person per day and over 20 people sharing
each latrine.15
Selection and enrollment of participants. This study used
samples collected from an oral cholera vaccine immuno-
genicity study,14 where individuals older than 1 year were
recruited from vaccination posts (and in some instances
households) during a mass oral cholera vaccination cam-
paign in June–July 2015. We enrolled an age-stratified con-
venience sample of participants who were willing to provide
blood on that day and expressed willingness to return for
additional follow-up visits (though only the first visit samples
are used here). All participants (and/or their guardians) pro-
vided written informed consent to participate in the study
including consent to use remaining samples for research on
other enteric pathogens like HEV.
Data collection. After providing informed consent, trained
study staff administered an electronic questionnaire to
participants collecting basic demographic data in addition to
details on where each person had resided before coming
to the camp and when he/she had arrived. After completion of
the questionnaire, a trained study nurse or phlebotomist drew
3–5 mL of venous blood into serum-separating vacutainers.
Within 12 hours, study laboratory technicians centrifuged the
blood and extracted serum. Serum was then stored at −20°C
or below until it was shipped on dry ice to the reference
laboratory at the University of Utah.
Testing of these specimens for HEV was within the original
scope of consent and was approved by the Johns Hopkins
Bloomberg School of Public Health and The Republic of
South Sudan ethical review boards.
Laboratory methods. Serum samples were tested for the
presence of anti-HEV IgG and IgM using an immunoassay kit
(Wantai HEV IgG [WE-7296], IgM [WE-7196] ELISA kits;
Beijing Wantai Biological Pharmacy Enterprise Co. Ltd.,
Beijing, China). Samples with a standardized optical density
> 1.1 were considered positive, those < 0.9 were considered
negative, and those in the range 0.9–1.1 were considered
indeterminate according to the manufacturer’s instructions.
Statistical analyses. We estimated the age-adjusted
seroprevalence using poststratification weights based on the
population age distribution from camp registration data
collected the same month as the data collection (International
Office ofMigration, internal report).Wald-type 95%confidence
intervals (CIs) were estimated taking into account this
adjustment using the “confint” command in R’s survey
package.16,17 We compared the relative risk of IgG posi-
tivity between different groups and estimated CIs as the
2.5th and 97.5th quantiles of 1,000 (age-adjusted) boot-
strap estimates.17
To determine whether being in the camp conferred any
increased HEV infection risk compared with that in individuals’
state of origin, we took two approaches ranging in complexity.
First, we simply compared the age-adjusted seroprevalence
of those who arrived in the camp in the first “wave” of dis-
placements (on or before January 1, 2014, N = 98) to those
who arrived within the 6 months before the survey (after
January 1, 2015, N = 59), with the hypothesis being that
those who have been in the camp the longest would have
higher anti-HEV seroprevalence if there was indeed trans-
mission in the camp.
Catalytic transmission models. Second, to compare the
force of infection (i.e., the rate per capita at which susceptible
individuals become infected, or hazard) in the camps to that in
the community where the displaced individuals came from, a
more direct measure of relative risk, we used the age-stratified
and location of origin–stratified seroprevalence curves to fit
catalytic transmission models.18 These models, which have
been used to estimate the historical force of infection for other
diseases,18–20 assume that seropositivity is a saturating state
and no IgG-positive individual will ever again be at risk
of infection.
The heterogeneity in arrival times of people of different ages
from different locations provides the information needed to
estimate the historical average forces of infection inside and
outside the camp. The probability that an individual was IgG
seropositive at the time of the study given the participants
age (a), his/her home state (s), and the time he/she spent in
the camp (tc, in 4-month intervals) wasmodeled as:
P þj a; s; tcð Þ ¼ 1 eλctcλsI a > tcð Þmin atc ;tmaxð Þ
where, λs represents the 4-month cumulative hazard of infec-
tion in the state of origin, λc the 4-month cumulative hazard
of infection in the camp, and tmax represents the maximum
historical time of exposure in a participant’s home state that
can contribute to these estimates (assumed to be 25 years in
the main analyses given the limited sample size and minimal
evidence of transmission decades ago21 [see Supplemental
Table 1 for alternative assumptions]).We used two different
variants of this model, one where the average 4-month cumu-
lative hazard of infection from each state of origin was
assumed equal (i.e., all λs’s were equal) and another where
each state had its own independent value.
We used a Bayesian framework and the Stan programming
language to estimate model parameters and assumed that
each observation came from a Bernoulli distribution with the
probability of positivity, as shown above. The hazards of
infection were estimated on the logit scale with diffuse
Gaussian priors (variance = 1,000) centered at a mean of zero.
We drew samples from the joint posterior distribution using the
standard built-in samplers in the RStan package in R.22We ran
four parallel chains, each with 7,000 iterations, and assessed
convergence visually and through use of the Gelman-Rubin (R^)
statistic.22 The estimates presented represent the posterior
means, and the 95% credible intervals (CrIs) are the 2.5th and
97.5th quantiles from the posterior distributions after a burn-in
period of 3,500 draws.
RESULTS
We enrolled 206 people between 1 and 59 years of age,
though most participants were older children and adults
and 131 (64%) were female. All participants were internally
displaced people who had arrived in the camp between
December 15, 2013 and May 7, 2015, fleeing from four
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different states: Central Equatoria, Jonglei, Upper Nile, and
Unity States of South Sudan.
Seroprevalence. Six samples had IgG levels that were
considered indeterminate and were (conservatively) consid-
ered negative, and 75% (154/206) were positive for anti-HEV
IgG. Since these samples did not come from a representative
sample of the camp population, they do not reflect the true
seroprevalence in the population. Using direct adjustment
methods, we estimated the age-adjusted seroprevalence of
HEV IgG to be 71% (95% CI = 63–78). In general, we saw
increasing seroprevalence with age (P = 0.0002 for linear rela-
tionship, Figure 1 and Supplemental Figure 1 and Table 2),
with consistently higher seroprevalence among females com-
pared with males (Supplemental Figure 2), although these dif-
ferences were not significant.
Although there had been no clinical cases of HEV
detected within the camp, we found nine samples (4.4%
adjusted and crude prevalence) positive for anti-HEV IgM,
all of whom were also IgG positive. One additional sample
was indeterminate for anti-HEV IgM. The IgM-positive indi-
viduals came from Unity State (N = 5), Central Equatoria
State (N = 3), and Jonglei State (N = 1) and reported arriving
to the camp 0.4–18 months before the start of the study
(interquartile range = 4.6–18.7 months).
While the overall seroprevalence increased by age (Figure 1
and Supplemental Figure 1), the study population represents a
mix of people with potentially different historical exposure to
HEV. Stratifying by location (i.e., state) of origin, we found
different seroprevalence patterns by age, depending on
location of origin (Figure 2 andSupplemental Figure 3). In those
coming from Central Equatoria and Upper Nile States,
seroprevalence increased with age, whereas in those coming
from Unity and Jonglei States, we found similar seropreva-
lence across most (or all) the age groups. Seroprevalence in
those coming from Central Equatoria was 63%, 61% from
Upper Nile, 85% fromUnity, and 81% from Jonglei.
Exposure risk in the camp. Combining individuals from all
home states, we found that those who had been in the camp
for at least 1.5 years had a 3% increased risk of being IgG
seropositive compared with those who arrived within the
6 months before the study, though this is likely confounded
by age and location of origin. To account for potential differ-
ences in historical exposure, we stratified by participants’
home state and found a higher risk of being seropositive
(42% increase in Central Equatoria, 79% increase in Jonglei,
25% increase in Upper Nile) in those who initially arrived in
the camp (on or before January 1, 2014) compared with those
who had come in the previous 6 months (after January 1,
2015), except for those coming fromUnity State (8% less).
To gain further insight into the age-adjusted risk of HEV
exposure in the camp compared with what the risk would
have been had they remained in their home state, we
constructed a catalytic transmission model to estimate the
force of infection in the camp and in each of the four home
states. We estimated a 2.4- to 5.3-fold increase in the haz-
ard of HEV in the camp compared with that estimated for
Central Equatoria State (hazard ratio [HR] = 5.3, 95% CrI =
0.8–15.0), Jonglei State (HR = 3.6, 95% CrI = 0.5–10.1),
Upper Nile State (HR = 4.4, 95%CrI = 0.6–13.4), and Unity
State (HR = 2.4, 95% CrI = 0.6–13.4), although none were
statistically significant. In an even simpler model, assuming
all home states had the same average historical 4-month
hazard of HEV exposure, we estimated a 2.3 (95% CrI =
0.3–5.8) times higher force of infection in the camp com-
pared with the participants’ previous residence. Within this
simple model, we estimate that 6.5% (95% CrI = 1–14.3%)
of susceptible individuals will have been exposed over
each 4-month period in the camp. Analyses with alterna-
tive assumptions yielded similar qualitative results, although
the HR decreased as we reduced the assumed number of
years that HEV had circulated in participants’ home states
(tmax, Supplemental Table 2).
DISCUSSION
In this study, we found a high seroprevalence of anti-HEV
(IgG) antibodies and evidence of recent exposure (IgM) in a
population of internally displaced people in South Sudan. Part
of this seroprevalence could be driven by recent transmission
in the states where the study participants originally came from,
for example, from Unity State, where an epidemic had been
ongoing.13 However, our results suggest that the risk of HEV
infection in the displaced person camp may have been, on
average, higher than in their home states, despite the absence
of documented clinical cases of acute jaundice (nor confirmed
HEV)within the camp.
HEV seroprevalence estimates from Africa vary widely
though seroprevalence estimates of over 60% within the
general population have not been found frequently, even
during or after large outbreaks.5,23 Even in “hyperendemic”
areas, including Nepal and Bangladesh, documented sero-
prevalence has typically been estimated at levels well below
those in this study.24 Our results suggest that in South Sudan,
there is more transmission than was previously thought with
potentiallymany unrecognized deaths related to the disease.
In displaced person camps, people from places with differ-
ent historical epidemiologic profiles come together and reside
in close quarters where conditions for disease spread are high.
In this study, subpopulations from each of the four home
states had different seroprevalence, with two age-specific
patterns emerging (Figure 2); first, a profile where sero-
prevalence rises with age, indicative of endemic circulation of
the virus; second, constant seroprevalence by age, suggestive
of a recent outbreak. This mix can result in a population-level
FIGURE 1. Seroprevalence of anti-hepatitis E virus (HEV) IgG by
age group. Red represents the proportion positive, blue represents
those negative, and yellow represents indeterminate readings.
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seroprevalence much different from that of any one location.
If seroprevalence is correlated with protection, this may leave
populations who were once protected by herd immunity in
their home state, residing in a camp with the potential for a
large outbreak. When assessing epidemic threat in mixed
populations, like in the camp in Juba, the different epidemio-
logic contexts where people came from should be considered.
This study comes with several limitations. First, our sam-
ple size was small, so that inference on subgroups, such as
age and state of origin, can only be made with limited pre-
cision. Our sample was a convenience sample; therefore,
participants may have differed in some ways from the gen-
eral population in factors related to HEV risk. Our classifica-
tion by previous state of residence is unlikely to be specific
enough to categorize people’s historical exposure to HEV,
both because we do not know if they had spent their entire
life in that state (e.g., they could have been in another camp
setting before) and due to variation in HEV exposure risk
within a state. Lastly, our models estimating the increased
risk within the camp are simplificaions of a complex his-
tory of human–pathogen interactions. For example, we esti-
mated the average 4-month hazard of HEV exposure over
the preceding 25 years in each participant’s home state,
which is likely comprised with periods of both high and low
exposure incidence. In sensitivity analyses, we found that
shortening the time window to as low as 15 years attenu-
ated estimates of the HR comparing risk in the camp to the
home states, although the point estimates remained above
one. Future studies with a larger sample size and more
detailed data could extend and improve these models by
accounting for known and unknown historical patterns in
transmission intensity.
The individuals who were IgM positive may not have been
indicative of transmission in the camp, as they may have been
exposed before arriving at the camp, or may have been false
positives. Some previous studies suggest that IgM wanes to
undetectable levels within 3–4 months,25,26 whereas others
have demonstrated that thismay be as long as 1 year for some
individuals.25,27,28 Most of the IgM-positive participants had
been in the camp for longer than 6 months, with some up to
1.5 years, suggesting it is unlikely they had been exposed
before coming. Given the high specificity of the IgM assay
used (> 99%), even in settings with low HEV prevalence, it is
highly unlikely to have nine false positives with the sample size
of this study.29 Further laboratory testing for viremia, which
has a shorter half-life than IgM,30 could shed more light on the
timing and location of these exposures.
Large protracted outbreaks have occurred in South Sudan,
particularly in camps, and our study provides new insights into
the dynamics of HEV transmission both in the camps and
across the country. When populations of susceptible people
enter camps with others coming from areas with endemic
FIGURE 2. Seroprevalence of anti-hepatitis E virus (HEV) IgG by age group and state of origin. Red represents the proportion positive, blue
represents those negative, and yellow represents indeterminate readings.
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transmission (or an ongoing outbreak), camp conditions
provide ample opportunities for hepatitis E epidemics to
explode. Although it has not been used to date outside
of China as a public health tool, hepatitis E vaccine could be
used to reduce the risk of outbreaks within this context. How-
ever, given the logistical constraints of the current three-dose
regimen, vaccination campaigns must act quickly, if not pre-
emptively, and not wait until large outbreaks are already
underway. There is hope that among those with previous
exposure to HEV, a shortened two-dose regimen may be effi-
cacious,31 thus allowing more adaptive outbreak response
with vaccine. However, more evidence from field studies or
clinical trials is needed to understand the utility of reduced
dose regimens.
Our study illustrates that HEV infections may be more
common than previously appreciated, suggesting the possibil-
ity of a higher (yet undetected) burden even outside of reported
outbreaks. Enhanced surveillance for HEV can help improve
our understanding of this disease and, if more clinical cases
are detected, it may strengthen the case to provide more
attention and resources to this vaccine-preventable disease.
In settings like South Sudan where large outbreaks have
occurred and evidence of high historical exposure exists, more
efforts should be put into the prevention and control of this
neglected disease to reduce future morbidity and mortality.
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